Real-World Evidence for Tenecteplase in Acute Stroke

Acute ischaemic stroke remains a leading cause of mortality and long-term disability worldwide. For decades, intravenous alteplase served as the standard thrombolytic therapy within the critical 4.5-hour therapeutic window. However, recent clinical advances highlight the efficacy and practical benefits of tenecteplase in acute stroke care. Tenecteplase is a genetically engineered variant of tissue plasminogen activator that boasts greater fibrin specificity and a longer plasma half-life. These pharmacokinetic properties enable single intravenous bolus administration, contrasting sharply with the cumbersome one-hour infusion required for alteplase. To evaluate how these pharmacological advantages translate into clinical practice, researchers conducted a massive real-world study across 18 stroke centres in China. The study analyzed 1,113 patients receiving tenecteplase and 2,360 patients receiving alteplase within 4.5 hours of symptom onset. To eliminate baseline selection bias, investigators applied rigorous propensity score matching, yielding 1,113 well-matched patient pairs. Consequently, this robust comparative study provides crucial real-world insights into safety, early neurological recovery, and long-term functional independence. Clinicians now have valuable data confirming that tenecteplase offers remarkable logistical convenience without compromising patient safety or clinical success.

Primary Safety Outcomes and Intracranial Hemorrhage Risk

Safety considerations remain paramount when initiating thrombolytic therapy for acute cerebral infarction. The primary safety outcome evaluated in this multicentre trial was the incidence of symptomatic intracranial haemorrhage within 72 hours post-thrombolysis. Remarkably, the rates of symptomatic intracranial haemorrhage were nearly identical between treatment arms, measuring 1.8% in the tenecteplase group and 1.98% in the alteplase group. Statistical analysis confirmed no significant difference between the two cohorts. Furthermore, secondary safety evaluations revealed additional compelling advantages for tenecteplase. Patients receiving tenecteplase demonstrated a significantly lower overall rate of any intracranial haemorrhage compared to those treated with alteplase, with an odds ratio of 0.51 and a 95% confidence interval ranging from 0.31 to 0.86. Similarly, researchers observed no significant differences between groups regarding parenchymal haemorrhage type 2, systematic bleeding events, or 90-day all-cause mortality rates. Consequently, these real-world safety findings provide reassuring evidence for emergency physicians and neurologists. Tenecteplase successfully achieves rapid thrombolysis without increasing the dangerous risk of intracerebral bleeding or systemic hemorrhagic complications.

Neurological Recovery and Early Improvement Metrics

Rapid reperfusion of ischaemic brain tissue is essential to stop the ischemic cascade and preserve viable neural tissue. In this comparative analysis, early neurological recovery was systematically measured using the National Institutes of Health Stroke Scale at 24 hours post-treatment. Patients who received tenecteplase achieved substantially higher rates of early neurological improvement at 24 hours compared to those treated with alteplase. Specifically, the odds ratio for early neurological improvement was 1.76, demonstrating a highly statistically significant advantage for tenecteplase. Furthermore, early neurological stabilization strongly correlates with reduced final infarct volumes and improved overall prognosis. The rapid mechanism of action inherent to tenecteplase allows swift thrombus dissolution, restoring microvascular cerebral perfusion earlier in the hyperacute phase. Consequently, patients experience accelerated clinical stabilization within the first 24 hours of hospital admission. These early neurological gains represent a critical milestone in stroke management, establishing a solid foundation for long-term physical recovery and reduced inpatient care burden.

Long-Term Functional Outcomes with Tenecteplase in Acute Stroke

While early recovery is crucial, the ultimate goal of stroke reperfusion therapy is restoring long-term functional independence. In this study, functional outcomes were rigorously evaluated at 90 days using the modified Rankin Scale shift analysis and categorical disability thresholds. Patients treated with tenecteplase demonstrated superior overall 90-day functional recovery compared to alteplase-treated patients, as evidenced by a favorable modified Rankin Scale shift with an odds ratio of 0.67. Moreover, a higher percentage of patients in the tenecteplase cohort achieved excellent functional outcomes, defined as a modified Rankin Scale score of 0 to 1, representing complete recovery or minimal symptoms. Specifically, tenecteplase yielded an odds ratio of 1.27 for achieving an mRS score of 0 to 1. Additionally, functional independence, defined as an mRS score of 0 to 2, was significantly higher in the tenecteplase group, with an odds ratio of 1.41. Therefore, these real-world findings confirm that tenecteplase delivers durable functional benefits that persist long after the hyperacute phase.

Logistical Superiority and Clinical Workflow Efficiency

Beyond clinical efficacy and safety, tenecteplase offers overwhelming practical and operational advantages over traditional thrombolytic regimens. Alteplase administration requires an initial intravenous bolus followed by a continuous one-hour infusion, necessitating dedicated infusion pumps and constant clinical monitoring. In contrast, tenecteplase is delivered as a single intravenous bolus over five to ten seconds. This rapid administration drastically simplifies emergency department workflow and eliminates delays associated with managing intravenous infusion lines. Furthermore, single-bolus administration is immensely beneficial when patients require urgent inter-facility transfer for endovascular thrombectomy. Transferring a patient with an active intravenous infusion introduces unnecessary risk and operational complexity. Consequently, replacing alteplase with tenecteplase streamlines bridging therapy, accelerates door-to-needle and door-to-groin puncture times, and reduces nursing workload during critical resuscitations. Therefore, adoption of tenecteplase optimizes health system resources while maintaining seamless continuity of care in busy stroke centers.

Clinical Recommendations and Future Practice Implications

The findings from this extensive Chinese real-world study add compelling weight to the growing global consensus supporting tenecteplase as the preferred thrombolytic agent for acute ischaemic stroke. By confirming non-inferior safety and superior efficacy in a real-world clinical environment, this research reinforces recent international guideline updates. Clinicians managing hyperacute stroke should feel confident transitioning from alteplase to tenecteplase within the standard 4.5-hour time window. Furthermore, health systems and emergency departments can leverage tenecteplase to improve institutional stroke response metrics and reduce length of stay in intensive care units. As stroke care networks continue to evolve, single-bolus thrombolysis will play a pivotal role in expanding access to rapid reperfusion therapy. Consequently, hospital administrators and clinical leads should update local stroke protocols, ensure adequate drug supply, and train emergency staff on standardized dosing regimens. Ultimately, adopting tenecteplase represents a progressive step toward modernizing emergency neurovascular care and improving patient survival without disability.

Frequently Asked Questions

What is the primary safety finding regarding tenecteplase in acute ischaemic stroke?

The study demonstrated that tenecteplase is as safe as alteplase, with no significant difference in symptomatic intracranial haemorrhage rates (1.8% vs 1.98%). Furthermore, tenecteplase was associated with a significantly lower overall rate of any intracranial haemorrhage, confirming its safety profile in real-world clinical practice.

How does tenecteplase improve functional recovery compared to alteplase?

Patients receiving tenecteplase achieved significantly higher rates of early neurological improvement at 24 hours. Furthermore, at 90 days post-treatment, tenecteplase-treated patients demonstrated superior overall functional independence, showing higher proportions of modified Rankin Scale scores of 0 to 1 and 0 to 2 compared with alteplase.

Why is single-bolus tenecteplase logistically advantageous in emergency stroke care?

Tenecteplase is administered as a single intravenous bolus over seconds, whereas alteplase requires a one-hour infusion. This rapid single-bolus delivery simplifies emergency workflow, reduces door-to-needle times, and facilitates smoother patient transfers for mechanical thrombectomy without managing continuous intravenous infusion pumps during transport.

Disclaimer: This content is for informational and educational purposes only, and should not be considered medical advice. Healthcare professionals should rely on their clinical judgment and refer to current treatment guidelines when making decisions. Refer to the latest local and national guidelines for clinical practice.

References

1. Liu Y et al. Tenecteplase thrombolytic therapy for acute ischaemic stroke in China: a real-world, multicentre, retrospective, controlled study. Stroke Vasc Neurol. 2025 Aug 26. doi: 10.1136/svn-2024-003381. PMID: 39537238.

2. Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a multicentre, open-label, randomised, controlled, non-inferiority trial. Lancet. 2022;400(10347):161-169.

3. Li S, Dai H, Lu G, et al. Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial. JAMA. 2024;332(22):1891-1901.